Breast cancer is the most commonly diagnosed cancer among women in China. It is also one of the most treatable major cancers when detected early and managed appropriately. Advances in screening, pathology, surgery, radiotherapy, endocrine therapy, HER2-targeted treatment, immunotherapy, and antibody-drug conjugates have transformed both survival and quality of life.
Calling breast cancer a “lucky cancer” can be misleading. Outcomes vary greatly by stage and biological subtype, and treatment can place a heavy physical and emotional burden on patients. A more accurate message is that modern breast cancer care offers many effective options, especially when diagnosis is timely and treatment is tailored to the individual.
Breast Cancer in China: A Growing and Changing Challenge
Breast cancer incidence has risen in China alongside population aging, lifestyle changes, greater public awareness, and wider access to screening. Chinese patients are often diagnosed at a younger age than those in many Western populations, making fertility, work, family responsibilities, body image, and long-term health especially important parts of care.
Risk is influenced by age, family history, inherited genetic variants, reproductive and hormonal factors, alcohol use, body weight after menopause, and previous chest radiation, among other factors. Most breast cancers are not caused by a single identifiable factor, and a diagnosis is never the patient’s fault.
For an overview of diagnosis and treatment resources in the city, read our breast cancer treatment guide for Shanghai.
The Logic of Subtype-Based Treatment
Breast cancer is not one disease. Treatment planning begins with the stage and pathology, including estrogen receptor, progesterone receptor, HER2 status, tumor grade, proliferation markers, lymph-node involvement, and other clinically relevant features. The major treatment groups are often described as hormone receptor-positive, HER2-positive, and triple-negative breast cancer.
Hormone Receptor-Positive / Luminal Breast Cancer
Luminal tumors express hormone receptors and may respond to endocrine therapy. Depending on menopausal status and recurrence risk, treatment can include tamoxifen, aromatase inhibitors, ovarian function suppression, CDK4/6 inhibitors, chemotherapy, or other medicines. Not every hormone receptor-positive patient needs chemotherapy; the decision should reflect stage, pathology, overall risk, age, general health, and, where appropriate, genomic testing.
HER2-Positive Breast Cancer
HER2-positive disease was once associated with aggressive behavior, but HER2-targeted medicines have substantially changed outcomes for many patients. Treatment may include anti-HER2 therapy with chemotherapy before or after surgery, while metastatic disease can involve additional targeted agents and antibody-drug conjugates. Cardiac monitoring may be necessary during certain treatments. Learn more in our HER2-positive breast cancer guide for international patients.
Triple-Negative Breast Cancer
Triple-negative breast cancer does not express estrogen receptors, progesterone receptors, or HER2. It is biologically diverse and may progress more quickly than some other subtypes. Treatment can include chemotherapy, immunotherapy for eligible patients, surgery, radiotherapy, PARP inhibitors for selected inherited mutations, and antibody-drug conjugates in appropriate settings.
Because treatment eligibility depends on stage, biomarkers, prior therapy, and regulatory availability, the plan should be made by an experienced breast oncology team. Our dedicated triple-negative breast cancer guide explains the Shanghai care pathway in more detail.
Shanghai’s Contribution: Building Care Around Chinese Patients
Fudan University Shanghai Cancer Center is one of China’s leading specialist cancer institutions. Its breast cancer teams have contributed to large clinical programs, multidisciplinary treatment, molecular classification, and research designed around the characteristics of Chinese patients.
The breast surgery group led by Prof. Shao Zhimin, together with specialists including Prof. Wu Jiong, has helped advance risk-adapted surgery and comprehensive treatment. Medical oncology specialists such as Prof. Hu Xichun focus on systemic treatment across different breast cancer subtypes and stages.
Patients can explore the clinical profiles of Prof. Shao Zhimin, Prof. Wu Jiong, and Prof. Hu Xichun in the CMCS Top Doctors library.
The value of a major breast center is not simply access to one specialist. It is the ability to coordinate breast surgery, medical oncology, radiation oncology, pathology, radiology, nuclear medicine, plastic surgery, rehabilitation, fertility care, and genetic counseling around one treatment strategy.
Early Detection: Screening Must Match the Patient
Earlier diagnosis generally creates more treatment options, but screening is not one-size-fits-all. A physician may recommend mammography, ultrasound, MRI, or a combination based on age, breast density, symptoms, family history, inherited risk, and previous findings.
A new lump, skin dimpling, nipple inversion, bloody discharge, persistent focal pain, or a change in breast shape should be assessed rather than delayed until the next routine screening appointment. Most breast findings are not cancer, but proper imaging and, when necessary, biopsy are essential.
Patients with a strong family history, very young age at diagnosis, bilateral disease, male breast cancer in the family, ovarian cancer, or other relevant patterns may be referred for genetic counseling. Genetic testing should be accompanied by professional interpretation because the result can affect surgery, medication choices, and family members.
Breast-Conserving Surgery and Reconstruction: From Survival to Quality of Life
Modern breast surgery aims to achieve cancer control while preserving function, appearance, and quality of life whenever medically appropriate. Breast-conserving surgery followed by radiotherapy may be an option for selected patients, while others may need or prefer mastectomy. The choice depends on tumor size and location, breast size, multifocal disease, genetic risk, response to preoperative treatment, radiation feasibility, and patient preference.
Sentinel lymph-node biopsy can reduce unnecessary axillary surgery in suitable patients, lowering the risk of arm swelling and shoulder dysfunction. When mastectomy is necessary, immediate or delayed reconstruction may use implants or the patient’s own tissue. Reconstruction is a personal choice, not a medical obligation, and it should never compromise safe cancer treatment.
Patients exploring reconstruction can read our post-cancer breast reconstruction feature.
New Hope in Triple-Negative Disease: Immunotherapy and ADCs
Triple-negative breast cancer remains a major clinical challenge, but treatment is changing quickly. For eligible early-stage patients, immunotherapy combined with chemotherapy may be considered before surgery and continued afterward according to the treatment protocol. In advanced disease, biomarker testing can help determine whether immunotherapy, a PARP inhibitor, or another targeted strategy may be appropriate.
Antibody-drug conjugates, often called ADCs, deliver a potent anticancer agent through an antibody directed toward a tumor-associated target. They have expanded options for some patients with previously treated metastatic breast cancer, including triple-negative and HER2-low disease. These medicines can cause significant side effects, including low blood counts, nausea, fatigue, lung injury, or other complications depending on the drug, so specialist selection and monitoring are essential.
Fertility, Menopause, Bone Health, and Sexual Health
For younger patients, fertility preservation should be discussed before chemotherapy or long-term endocrine treatment whenever time and medical safety allow. Options may include egg or embryo freezing and, in selected situations, ovarian tissue preservation. Pregnancy planning after breast cancer requires coordination between oncology and reproductive specialists.
Long-term endocrine treatment can affect menstrual function, menopausal symptoms, bone density, cardiovascular risk, sleep, mood, and sexual health. These concerns are part of cancer care, not optional extras. Patients should tell their medical team about symptoms rather than stopping therapy without guidance.
Lifelong Follow-Up and Whole-Patient Management
Breast cancer care continues after surgery, chemotherapy, or radiotherapy ends. A practical survivorship plan may include:
- Recurrence surveillance: scheduled clinical review and breast imaging based on the operation and individual risk;
- Medication adherence: monitoring endocrine or targeted therapy and managing side effects early;
- Lymphedema prevention and rehabilitation: shoulder mobility, arm care, and prompt assessment of swelling or heaviness;
- Bone and cardiovascular health: appropriate monitoring during endocrine and HER2-targeted treatments;
- Nutrition and physical activity: maintaining a healthy weight and gradually returning to regular exercise when medically safe;
- Emotional and social recovery: addressing anxiety, body image, intimacy, family communication, and return to work;
- Record continuity: keeping pathology, receptor results, imaging, genetic testing, operation notes, drug doses, and radiotherapy details organized.
New symptoms should be evaluated, but routine follow-up should also avoid unnecessary scans and tumor-marker testing when they are not clinically indicated. The treating team should define a personalized schedule.
How CMCS Supports International Patients in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize medical information, identify appropriate specialists in Shanghai, and coordinate care before, during, and after appointments.
Depending on the case, CMCS can assist with:
- Organizing pathology, receptor testing, molecular reports, mammography, ultrasound, MRI, CT, and PET-CT files;
- Coordinating evaluation by breast surgery, medical oncology, radiation oncology, plastic surgery, or a multidisciplinary team;
- Preparing a concise bilingual case summary and a prioritized consultation question list;
- Supporting appointment planning, travel preparation, on-site communication, and examination scheduling;
- Helping patients track treatment milestones, follow-up dates, and side-effect concerns;
- Facilitating necessary communication with family members after receiving the patient’s authorization.
Remote medical record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent records before case coordination. CMCS can usually address approximately three to five core questions during initial screening. If specific coordination is required, the service scope and applicable fee will be explained in advance.
Conclusion: Treat the Cancer, Protect the Life Around It
Breast cancer treatment has moved beyond a single goal of removing the tumor. Precision classification guides therapy, multidisciplinary planning protects safety, and breast conservation, reconstruction, fertility support, rehabilitation, and survivorship care help preserve quality of life.
From early detection to long-term follow-up, the best plan is one that treats both the disease and the person living through it.
Contact CMCS
For help organizing breast cancer records, connecting with appropriate specialists in Shanghai, or planning a medical visit, contact us:
- Website: www.medicalsh.com
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
You may also submit your information through our contact page.
Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment advice. Screening, testing, medication, surgery, and follow-up plans must be determined by qualified physicians using the patient’s complete medical information.
0 則留言